Garsorasib
As of the edition of 20 October 2026, Garsorasib is a small molecule: in active development; acts on KRAS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 12, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KRAS | GTPase KRas | P01116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 8 | 1 | 6 | 1 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| InventisBio | Lead sponsor of trials | 2020 to now |
| InxMed | Lead sponsor of trials | 2022 to now |
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2024 to now |
| Suzhou Genhouse Bio | Lead sponsor of trials | 2024 to now |